ThomasMHabermannMD

PubMed

• Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.
  Allison M Bock, Kerstin Wenzl, Joseph P Novak, Matthew E Stokes, Melissa A Hopper
  Hematological Oncology. 2025-01-01
• 1 citations
  Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screening.
  Suheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, Robyn L Kuchler, Grzegorz S Nowakowski
  American Journal of Hematology. 2025-01-01
• Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
  Côme Bommier, Brian K Link, Brianna J Gysbers, Matthew J Maurer, Melissa C Larson
  Blood Advances. 2024-12-10

Journal Articles

• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Publisher Correction: Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes  
  Thomas M Habermann, Scott J Rodig, Rameen Beroukhim, Jeremiah A Wala, Andrew L Feldman, Todd R Golub, Margaret A Shipp, Nature
• Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome for Patients with Diffuse Large B-cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials  
  Thomas Habermann, MD, Annals of Oncology

Abstracts/Posters

• Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An Internation...
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease? 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all